PROCEPT BioRobotics Corp
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PRCT$23.05+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss F-
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue | $224,498 | $136,191 | $75,014 |
| Cost of sales | 87,399 | 65,142 | 37,929 |
| Gross profit | 137,099 | 71,049 | 37,085 |
| Operating expenses: | |||
| Research and development | 62,298 | 48,446 | 28,981 |
| Selling, general and administrative | 171,415 | 131,773 | 88,828 |
| Total operating expenses | 233,713 | 180,219 | 117,809 |
| Loss from operations | (96,614) | (109,170) | (80,724) |
| Interest expense | (4,184) | (3,995) | (5,183) |
| Interest and other income, net | 9,385 | 7,268 | 2,011 |
| Loss on loan extinguishment | — | — | (3,258) |
| Net loss | $(91,413) | $(105,897) | $(87,154) |
| Net loss per share, basic and diluted | $(1.75) | $(2.24) | $(1.96) |
| Weighted-average common shares used to | |||
| compute net loss per share attributable to | |||
| common shareholders, basic and diluted | 52,125 | 47,255 | 44,400 |
| Other comprehensive gain (loss): | |||
| Unrealized gain on cash equivalents | 30 | 90 | 48 |
| Comprehensive loss | $(91,383) | $(105,807) | $(87,106) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.